BURLINGTON, Mass., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Palomar Medical Technologies, Inc., a leading researcher and developer of light-based systems for aesthetic treatments, is pleased to announce that the MaxG™ Optimized Pulsed Light™ (OPL) handpiece is now available worldwide for use on the company's StarLux® 500 and Artisan™ laser and pulsed light aesthetic systems. The MaxG optimized light handpiece has established a new level of clinical performance and client experience in using light to clear undesired vascular and pigmented lesions. As compared to the MaxG, competitive pulsed light devices do not have the targeted wavelengths, sufficient power, or smooth pulse shape necessary to satisfy today's aesthetic demands. The MaxG utilizes a unique combination of dual-band filters and Dynamic Spectrum Shifting™ which provides more uniform heating across the entire diameter of larger vessels, for the most complete vessel clearance. Emil Tanghetti, MD, founder of the Center for Dermatology and Laser Surgery in Sacramento, CA, stated, "I believe that the StarLux 500 with the MaxG handpiece is just as good as, if not better than, modern pulse dye lasers in the treatment of facial telangiectasia." Robert Weiss, MD, founder of the Maryland Laser, Skin, and Vein Institute in Hunt Valley, MD, added, "We have also seen port wine stains respond to the MaxG when all else has failed. I am impressed with the immediate photodarkening and subsequent response with resistant port wine stains. Patient comfort is impressive as well." Joseph P. Caruso, Chief Executive Officer, concluded, "The MaxG is the latest in a long line of pulsed-light innovations from Palomar. The MaxG introduces a new generation of optimized light technology to the aesthetic industry that builds upon our proven technologies, combining the comfort of pulsed light with the clinical performance of lasers. We are very pleased that leading dermatologists are embracing this new technology so quickly."
Additional information about the MaxG may be found in a special clinical supplement, "Pushing the Spectrum: Optimizing Treatment of Vascular and Pigmented Lesions" in the December 2010 issue of Dermatology Times. Palomar will also conduct a live web seminar, hosted by Robert Weiss, MD and Vic Narurkar, MD on December 9, 2010. Viewers may register for the webinar at palomarmedical.com.About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of light-based systems for aesthetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. As a pioneer of fractional technology, Palomar is an owner of fundamental intellectual property in this area. In December 2009, Palomar received the first FDA clearance for the treatment of stretch marks using a fractional non-ablative laser. In September 2010, Palomar received the first FDA clearance for a fractional ablative and fractional non-ablative combination treatment. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, laser device for the treatment of periorbital wrinkles. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based aesthetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the aesthetic market and other surgical applications. For more information on Palomar and its products, visit Palomar's website at www.palomarmedical.com.
CONTACT: Palomar Medical Technologies, Inc. Branden Morris (781) 993-2452 email@example.com